CLYM21085 / A051902 / Casulo
Basic Study Information
Purpose:
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy
consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone
in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy
drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone,
work in different ways to stop the growth of cancer cells, either by killing the cells,
by stopping them from dividing, or by stopping them from spreading. This trial may
help find out if this approach is better or worse than the usual approach for treating
peripheral T-cell lymphoma.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Carla Casulo
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search